Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004

Opsoclonus-myoclonus syndrome (OMS) is a rare neurologic syndrome that, in children, associates with neuroblastoma in more than half of the cases. The etiology of this condition is thought to be immune mediated, but, though immunosuppressive therapies may ameliorate the acute symptoms, no effective...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2005-10, Vol.228 (1), p.275-282
Main Authors: Matthay, Katherine K., Blaes, Franz, Hero, Barbara, Plantaz, Dominique, De Alarcon, Pedro, Mitchell, Wendy G., Pike, Michael, Pistoia, Vito
Format: Article
Language:English
Subjects:
Ataxia
Behavior
Cancer
Cancer therapies
Chemokines
Clinical features
Eyes & eyesight
Humans
Hypotheses
Immune system
Immunopathogenesis
Immunosuppressive Agents - therapeutic use
Lymphocytes
Neuroblastoma
Neuroblastoma - complications
Neuroblastoma - physiopathology
Novel therapies
Opsoclonus-myclonus syndrome
Paraneoplastic Syndromes, Nervous System - complications
Paraneoplastic Syndromes, Nervous System - drug therapy
Paraneoplastic Syndromes, Nervous System - physiopathology
Pathogenesis
Patients
Pediatrics
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Opsoclonus-myoclonus syndrome (OMS) is a rare neurologic syndrome that, in children, associates with neuroblastoma in more than half of the cases. The etiology of this condition is thought to be immune mediated, but, though immunosuppressive therapies may ameliorate the acute symptoms, no effective treatment to prevent the common neuropsychologic sequelae has been established. This paper summarizes the results obtained at the 2004 Advances in Neuroblastoma Research meeting, providing status of the art information on immune pathogenesis, clinical features, acute and chronic neurologic manifestations, current and novel therapeutic approaches. It is emphasized that, due to the rarity of OMS in general and neuroblastoma-associated OMS in particular, international collaborations are needed to better define the pathogenesis and therapy of this disease, propose common evaluation criteria and identify new treatment modalities.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2005.01.051